Loading stock data…
$4.19+0.02 (+0.48%)
Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. in the Healthcare sector is trading at $4.19 with a market capitalization of $198M. Wall Street consensus targets $7.00 (1 analysts), implying a +67.1% move over the next 12 months. The stock is currently 23% below its 52-week high of $5.47, remaining 5.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$2.77M↑ | -$3.66M↑ | -$5.67M↓ | -$2.43M↑ | -$2.49M |
| Net Income | $78.16M↑ | $38.31M↑ | $10.01M↓ | $48.40M↑ | $13.29M |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical t...